Theranostics Application of Graphene-Based Materials in Cancer Imaging, Targeting and Treatment

Recent advancements in graphene-based nanomaterials provide the opportunity that compliments the limitations of conventional drug delivery systems (DDSs) through simultaneous targeting of the anticancer drug to the cancer cell by reducing the side effects of other administration routes. Graphene with its extraordinary electronic properties like larger surface area, possibilities of surface modification, can efficiently target the tumor cell. At the same time, nanocarriers have the advantages of immune clearance adulteration of physicochemical properties of anticancer drug. The DDSs can be made by biodegradable nanocarriers such as proteins, peptides, biocompatible polymers, antibodies, polymer-drug conjugates, etc. Graphene-supported DDSs in cancer therapy also supports the co-delivery of therapeutic agents, antioxidants, SiRNA, shRNA, etc. as the co-delivery approach, which provide additive or synergistic therapeutic efficacy and can reduce toxic effects

Strictly non-blocking conditions for the central-stage buffered Clos-network

We consider using the Clos-network to scale high performance routers, especially the Space-Memory-Space (SMS) packet switches. In circuit switching, the Clos-network is responsible for pure connections and the internal links are the only blocking sources. In packet switching, however, the buffers cause additional blockings. In this letter, we first propose a scalable packet switch architecture that we call the Central-stage Buffered Clos-network (CBC). Then, we analyze the memory requirements for the CBC to be strictly non-blocking, especially for emulating an output-queuing packet switch. Results show that even with the additional memory blockings the CBC still inherits advantages from the Clos-network, e.g., modular design and cost efficiency